Cargando…

Intratumoral PD-1(+)CD8(+) T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer

BACKGROUND: Although PD-1 has been reported to be a marker of T-cell exhaustion in several malignancies, the biological role of PD-1(+)CD8(+) T cells in gastric cancer (GC) remains unclear. Herein, we aimed to investigate the role of PD-1(+)CD8(+) T cells in the tumour microenvironment and its clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Kuan, Gu, Yun, Zhang, Puran, Fang, Hanji, Cao, Yifan, Wang, Jieti, Lin, Chao, Liu, Hao, Zhang, Heng, He, Hongyong, Li, Ruochen, Qin, Jing, Li, He, Xu, Jiejie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596411/ https://www.ncbi.nlm.nih.gov/pubmed/36002752 http://dx.doi.org/10.1038/s41416-022-01939-8

Ejemplares similares

Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer
por: Zhang, Puran, et al.
Publicado: (2022)

Intratumoral CXCR5(+)CD8(+)T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer
por: Wang, Jieti, et al.
Publicado: (2021)

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy
por: Gu, Yun, et al.
Publicado: (2022)

Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response
por: Fang, H., et al.
Publicado: (2020)

Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer
por: Xu, Chang, et al.
Publicado: (2022)

Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients
por: Jin, Kaifeng, et al.
Publicado: (2021)

CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients
por: Cao, Yifan, et al.
Publicado: (2016)

Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer
por: Xia, Siyu, et al.
Publicado: (2021)

Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer
por: Lv, Kunpeng, et al.
Publicado: (2023)

C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer
por: Liu, Xin, et al.
Publicado: (2023)

Intratumoral CD103(+)CD4(+) T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients
por: Gu, Yun, et al.
Publicado: (2020)

Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103(+)CD8(+) T cells conferring favourable prognosis
por: Li, Ruochen, et al.
Publicado: (2020)

Tumor-infiltrating podoplanin(+) cells in gastric cancer: clinical outcomes and association with immune contexture
por: Liu, Xin, et al.
Publicado: (2020)

Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer
por: Cao, Yifan, et al.
Publicado: (2016)

Tumor‐infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer
por: Wang, Jie, et al.
Publicado: (2018)

High expression of C-C chemokine receptor 2 associates with poor overall survival in gastric cancer patients after surgical resection
por: Li, Ruochen, et al.
Publicado: (2016)

Interleukin-13 receptor α2 is associated with poor prognosis in patients with gastric cancer after gastrectomy
por: Lin, Chao, et al.
Publicado: (2016)

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients
por: Bo, Xiaobo, et al.
Publicado: (2018)

Immunoscore Signature Predicts Postoperative Survival and Adjuvant Chemotherapeutic Benefits in Esophageal Squamous Cell Carcinoma
por: Zhuge, Lingdun, et al.
Publicado: (2020)

Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles
por: Sitthirak, Sirinya, et al.
Publicado: (2022)

Prognostic value of stromal cell-derived factor 1 expression in patients with gastric cancer after surgical resection
por: Wang, Xuefei, et al.
Publicado: (2014)

Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma
por: Yang, Zhi-Zhang, et al.
Publicado: (2017)

High expression of galectin-7 associates with poor overall survival in patients with non-metastatic clear-cell renal cell carcinoma
por: Wang, Jieti, et al.
Publicado: (2016)

Decreased expression of granulocyte-macrophage colony-stimulating factor is associated with adverse clinical outcome in patients with gastric cancer undergoing gastrectomy
por: Liu, Hao, et al.
Publicado: (2017)

B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients
por: Xie, Huyang, et al.
Publicado: (2018)

Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer
por: Liu, Qi, et al.
Publicado: (2019)

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
por: Yan, Sen, et al.
Publicado: (2022)

A Prehepatectomy Circulating Exosomal microRNA Signature Predicts the Prognosis and Adjuvant Chemotherapeutic Benefits in Colorectal Liver Metastasis
por: Wang, Yun, et al.
Publicado: (2021)

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
por: Cloughesy, Timothy F., et al.
Publicado: (2019)

Tumor-infiltrating IL-17A(+) cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer
por: Wang, Zewei, et al.
Publicado: (2020)

Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser
por: Omland, Silje Haukali, et al.
Publicado: (2022)

High Intratumoral Expression of Tetranectin Associates with Poor Prognosis of Patients with Gastric Cancer after Gastrectomy
por: Chen, Hao, et al.
Publicado: (2017)

Radiomics signature of computed tomography imaging for prediction of survival and chemotherapeutic benefits in gastric cancer
por: Jiang, Yuming, et al.
Publicado: (2018)

High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer
por: Ke, Shouyu, et al.
Publicado: (2022)

Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer
por: Gao, Xianchun, et al.
Publicado: (2023)

PD-L1 and intratumoral immune response in breast cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2017)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2021)

Stathmin 1 expression predicts prognosis and benefits from adjuvant chemotherapy in patients with gallbladder carcinoma
por: Bo, Xiaobo, et al.
Publicado: (2017)

Surgeons’ mental distress and risks after severe complications following radical gastrectomy in China: a nationwide cross-sectional questionnaire
por: He, Hongyong, et al.
Publicado: (2023)

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer
por: Ma, Gui-Fen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_25b04otpejuhpmpqe1e98375p1